AstraZeneca and Genentech Checkpoint Inhibitors Improve Survival in Two Different Lung Cancers
ASTRAZENECA AstraZeneca’s (AZN) Checkpoint Inhibitor Imfinzi significantly improved Overall Survival (OS) for Stage III Non-Small Cell Cancer Imfinzi …
Roche (RHHBY)
Real Breakthroughs
This content is for members
The FDA Grants Breakthrough Therapy Designation for Balovaptan – Roche’s Product for Autism Spectrum Disorder (ASD)
Yes, the title is real and correct and the condition is ASD and US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for …
Last Week’s Promising News
This content is for members
Prohost Letter #413
This content is for members
Two Large Pharma Agreements with Halozyme in One Day. HALO Rallied
This content is for members
Why Scientists Are Now Optimistic Zeroing in on Neurodegenerative Diseases
New Discoveries in Neurodegenerative Diseases Everyday is another day that can totally differ from the previous day with regard to increasing researchers’ …
Prohost Letter #412 Part 3
This content is for members
Prohost Letter #411
This content is for members
Prohost Letter #410
This content is for members
The Value of Sangamo, Merck and AstraZeneca News
This content is for members
Who Is the New FDA Commissioner? What Happened to Roche’s Immunotherapy Drug?
AT A GLANCE IMPORTANT NEWS A New FDA Commissioner The U.S. Senate Voted in Favor of Scott Gottlieb as the FDA Chief – Dr. Gottlieb, a medical doctor …
Prohost Letter #405
This content is for members
Why Amgen Is Still King. Why Roche Allergic Asthma Drug Xolair Is Becoming a Blockbuster.
This content is for members